Blue Cross Blue Shield · Hereditary Cancer Panel · US health-plan appeal rights

Hereditary Cancer Panel denied for failing step therapy by Blue Cross Blue Shield?

Q: How long do I have to appeal a Blue Cross Blue Shield Hereditary Cancer Panel denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Blue Cross Blue Shield typically requires

Blue Cross Blue Shield's specific coverage criteria for hereditary cancer panel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: BCBSA Evidence Street + Avalon Healthcare Solutions Trusted Lab Network (most BCBS); Anthem uses AIM/Carelon

The Blue Cross Blue Shield angle on Hereditary Cancer Panel

## Why This Denial Happens

Some BCBS plans apply a step-therapy or sequential-testing requirement to hereditary cancer panels, requiring that a narrower single-gene or small-panel test be performed before a comprehensive multi-gene panel is authorized. This approach reflects older clinical paradigms in which testing was done gene-by-gene based on phenotype. It is increasingly at odds with current clinical practice, which favors comprehensive panel testing at the outset when the clinical presentation does not point to a single gene, because panels are often more cost-effective and diagnostically informative than sequential single-gene tests.

## Why This Is Appealable

Step-therapy denials for genetic testing are appealable when the ordering clinician documents that the required prior step is clinically inappropriate, has already been performed, or would result in a clinically inferior or more costly diagnostic pathway. Many states have enacted step-therapy exception laws that require plans to grant exceptions when a prior step is contraindicated or otherwise clinically inappropriate. Even without a state law, BCBS must provide an individualized exception process; the appeal effectively functions as that exception request.

## Federal Appeal Framework

Internal appeal: File within the deadline on the denial notice. Frame the appeal as both an appeal and a formal step-therapy exception request.
External review (ACA §2719): After final internal denial, independent external review is available — generally within four months. The external reviewer will assess whether application of the step-therapy requirement was clinically appropriate for this patient.
Expedited review: Request when the patient's clinical situation requires timely results for treatment planning.
State step-therapy reform law: Check whether your state has enacted step-therapy exception legislation; if so, cite it in the appeal and note that BCBS is required to grant an exception when the criteria are met.
ERISA §503: Applies to self-funded plans; full-and-fair review and federal court access after exhaustion.

## Documentation to Gather

1. Ordering clinician's letter — explaining why a comprehensive panel is clinically appropriate as the first-line test for this patient, and why the required prior step (single-gene or limited panel) is clinically inadequate or inappropriate for this presentation. 2. Prior testing records — if any prior genetic testing has already been performed, include the records to document what was tested and why it was insufficient. 3. Applicable guideline organization's current recommendation — reference the organization (e.g., NCCN) and submit the current guideline document supporting upfront comprehensive panel testing in this clinical context. 4. Clinical and family history — detailed documentation establishing the clinical indication and why the diagnostic picture requires comprehensive gene coverage. 5. BCBS step-therapy exception criteria — obtained from the denial notice or BCBS's published policy — to ensure the appeal addresses each criterion directly.

## Criteria-Mapping Structure

List each step-therapy exception criterion from BCBS's policy in a two-column table. On the right, provide the exact supporting clinical fact. The most powerful arguments are: (a) the required prior step is clinically contraindicated or inappropriate for this patient's specific presentation; (b) the prior step has already been completed and was inadequate; or (c) the relevant guideline organization explicitly recommends comprehensive upfront testing for this clinical scenario. Attach the guideline document and the ordering clinician's signed letter as labeled exhibits.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Blue Cross Blue Shield appeals

Other insurers on Hereditary Cancer Panel

Other denial reasons for Blue Cross Blue Shield Hereditary Cancer Panel

denied as not medically necessary denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.